Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02227446 · ClinicalTrials.gov registry record · Phase 3
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
A Phase 3 study, sponsored by Major Extremity Trauma Research Consortium.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,036
- Enrollment target
NCT02227446: Completed Phase 3 study, sponsored by Major Extremity Trauma Research Consortium.
NCT02227446 is a Phase 3 study that has completed, run by Major Extremity Trauma Research Consortium. The registered enrollment target is 1,036 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02227446, a Phase 3 study, has completed, sponsored by Major Extremity Trauma Research Consortium.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,036 participants
- Enrollment target
Study Summary
The Vancomycin Study is a multi-center, prospective randomized controlled trial that will compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder at the time of fracture fixation.
Primary Outcome
The main outcome will be the presence of clinically significant surgical site infection (SSI) in the first 26 weeks after surgery, as determined by CDC guidelines. The CDC criteria is currently 3 months for surgical site infection. To help capture more infections the study investigators have moved the time frame back to 6 months. Wound characteristics will also be evaluated using the ASEPSIS score. In this system wounds are scored using the weighted sum of points assigned for predetermined crit
Interventions
- DRUG Vancomycin antibiotic powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,036 participants |
| Start Date | 2014-10 |
| Est. Completion | 2019-11 |
| Phase | Phase 3 |
What the finished NCT02227446 record still lists
NCT02227446 is an interventional study that assigns participants to a tested intervention. Its 1,036 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% higher).
The record links to 0 conditions, and to 1 intervention - of which Vancomycin antibiotic powder is the first listed.
NCT02227446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02227446 about?
NCT02227446 is a clinical study titled "Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)". The Vancomycin Study is a multi-center, prospective randomized controlled trial that will compare the proportion of deep surgical site infections within 6 months in patients treated with local Vancomycin powder compared to those treated without local Vancomycin powder at the time of fracture fixatio...
What is the current status of trial NCT02227446?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,036 participants. The study started on 2014-10. Estimated completion is 2019-11.
What interventions are being tested in trial NCT02227446?
The interventions under investigation include: Vancomycin antibiotic powder (DRUG).
Who is sponsoring clinical trial NCT02227446?
This trial is sponsored by Major Extremity Trauma Research Consortium, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02227446's enrollment target sits among peer trials
1,036 287th of 2000 higher than 1,714 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05037682 · 1,035 participants · NA
Pain and Opioid Management in Older Adults
- NCT07282600 · 1,035 participants · Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- NCT07345767 · 1,038 participants · NA
Hypknowledge Nationwide Sleep Extension
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia